Cladribine for treating relapsing-remitting multiple sclerosis

Cladribine is in clinical development for the treatment of relapsing-remitting multiple sclerosis (MS). MS is a disease that impacts the brain, spinal cord, and optic nerves, which make up the central nervous system (CNS). The cause of MS is not fully clear, but in MS, the immune system attacks the CNS which causes damage to the nerves. This results in unpredictable symptoms such as numbness, tingling, mood changes, memory problems, pain, fatigue, blindness and/or paralysis. Relapsing remitting MS is where you have relapses (symptoms getting worse) followed by recovery (“remitting”). Relapsing-remitting MS is the most common form of MS.